Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 December 2021Website:
http://www.immixbio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:36:11 GMTDividend
Analysts recommendations
Institutional Ownership
IMMX Latest News
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum.
Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall response rate in patients with multiple myeloma. They also have a tissue-specific platform called iMX-110, which is being assessed in early-stage studies for sarcoma and colorectal cancer.
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit.
Immix Biopharma, Inc. (IMMX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.
A high-ranking official at the Federal Reserve has indicated that the US central bank is planning to maintain its benchmark interest rate during its September policy meeting. This decision comes in response to recent economic data, which, according to the official, does not warrant any immediate need for additional monetary tightening.
What type of business is Immix Biopharma?
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
What sector is Immix Biopharma in?
Immix Biopharma is in the Healthcare sector
What industry is Immix Biopharma in?
Immix Biopharma is in the Biotechnology industry
What country is Immix Biopharma from?
Immix Biopharma is headquartered in United States
When did Immix Biopharma go public?
Immix Biopharma initial public offering (IPO) was on 16 December 2021
What is Immix Biopharma website?
https://www.immixbio.com
Is Immix Biopharma in the S&P 500?
No, Immix Biopharma is not included in the S&P 500 index
Is Immix Biopharma in the NASDAQ 100?
No, Immix Biopharma is not included in the NASDAQ 100 index
Is Immix Biopharma in the Dow Jones?
No, Immix Biopharma is not included in the Dow Jones index
When does Immix Biopharma report earnings?
The next expected earnings date for Immix Biopharma is 09 August 2024